Pilot Study of the Paclitaxel, Oxaliplatin, and Cisplatin Combination in Patients With Advanced/Recurrent Ovarian Cancer
| Autor: | J.L. Misset, A. Taamma, Suzette Delaloge, Patricia Pautier, Nadia Chouaki, Esteban Cvitkovic, Catherine Lhommé, Abderahmane Laadem |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
Adult
Cancer Research medicine.medical_specialty Organoplatinum Compounds Paclitaxel medicine.medical_treatment Pilot Projects Neutropenia Gastroenterology chemistry.chemical_compound Internal medicine Antineoplastic Combined Chemotherapy Protocols Granulocyte Colony-Stimulating Factor medicine Humans Aged Neoplasm Staging Ovarian Neoplasms Cisplatin Chemotherapy business.industry Cancer Middle Aged medicine.disease Oxaliplatin Surgery Oncology chemistry Toxicity Feasibility Studies Female business Febrile neutropenia medicine.drug |
| Zdroj: | American Journal of Clinical Oncology: Cancer Clinical Trials. 23:569-574 |
| ISSN: | 0277-3732 |
| DOI: | 10.1097/00000421-200012000-00007 |
| Popis: | To determine the feasibility of the paclitaxel, oxaliplatin, cisplatin combination in advanced ovarian cancer (AOC), 15 patients with AOC (8 chemonaive, and 7 second-line, disease-free interval > or = 12 months) received paclitaxel 135 mg/m2 at day 1, with oxaliplatin 100 mg/m2 and cisplatin 75 mg/m2 at day 2, every 3 weeks for 6 cycles. Pretreated patients received prophylactic granulocyte colony-stimulating factor (5 microg/kg/d, days 6-13). Seventy cycles were administered; median 5 (range: 2-6 cycles) in chemonaive, and 4 (range: 2-6) in pretreated patients. There were grades III to IV neutropenia in 77%, febrile neutropenia in 24%, and grades III to IV thrombocytopenia in 4% of the cycles. Besides neutropenia, cumulative neurosensory toxicity was also limiting although reversible, with National Cancer Institute Common Toxicity Criteria grades II to III observed in 13 patients. Three of the pretreated patients had complete responses (43%), three had partial responses, and one had disease stabilization. Six of the 8 chemonaive patients had complete responses (75%), 1 had disease stabilization, and 1 had disease progression. The median follow-up is 17 months (range: 9-20 months) in chemonaive and 41 months (range: 13-58 months) in pretreated patients, and time to progression has been consistently more than 12 months, with 6 patients (5 chemonaive) still progression free (range: 15+ to 22+ months). This active combination shows acceptable hematologic toxicity, and reversible cumulative neurosensory toxicity. Further clinical exploration of the present combination appears warranted. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|